Answers are grounded in this paper and cite their sources.
The impact of cisplatin on chemotherapy for solid tumors has led to the synthesis of many molecules with platinum as their central building block. These so-called platinum analogues have been developed with the obvious goals of improving the antitumor activity of cisplatin and hopefully, at the same time, altering the dose-limiting side effects of the prototype drug. At least 10 such molecules are in clinical development, whereas several others are at various stages of preclinical testing.
No takes yet. Share an insight, caveat, or question.
Hamilton et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: